The supplied corpus attributed to "Minho Lee" spans at least 10 distinct fields over three decades: neuro-fuzzy control theory (1994), DFT materials physics (2014), mast-cell immunology (2017), orthopedic surgery (2017), chromatin biology (2019), semiconductor reliability (2020), microbiome multi-omics (2022), and five 2026 works spanning nanomedicine, antibody engineering, Alzheimer's disease, antimicrobial resistance, and plant pathology. This breadth strongly suggests either multiple authors sharing the name or an exceptionally prolific multidisciplinary scientist. An OpenAlex author-resolution attempt returned a 429 rate-limit error, leaving disambiguation unresolved.
The most rigorous work is the BET-family study (scored 9/10 quality, 9/10 novelty), which combined RNA-seq, ChIP-seq, GRO-seq, knockdown rescue experiments, and clinical GOBO survival correlations to delineate redundant versus unique roles of BRD2/3/4 at ERΞ± enhancers, with public GEO data deposition (GSE109570, GSE109571) enabling independent verification . The weaning-pig multi-omics study (quality 8, novelty 9) integrated 16S metagenomics, culturomics, and metabolomics to link Lactobacillus enrichment to BCAA metabolism and barrier-gene upregulation, with BioProject data availability .
The Mn-ZIF nanomedicine study (quality 8.5) used systematic inhibitor-rescue panels (ferrostatin-1, liproxstatin-1 rescued; zVAD-fmk and necrostatin-1 did not) to narrow the mechanism to ferroptosis-like death, though GPX4/molecular confirmation was absent and only two 2D cell lines were tested . The roxatidine immunology study (quality 7) used both HMC-1 in vitro and two mouse models but relied on the HMC-1 cell line rather than primary mast cells with n=6 per group . The 1994 neuro-fuzzy work (quality 8, novelty 8) provided theoretical stability proofs but was simulation-only .
The AMR narrative review scored lowest (quality 5, reproducibility 3) due to absence of systematic search or meta-analytic methodology . The dual-targeted LNP/CAR preprint used cells from a single healthy donor with no inferential statistics, limiting population-level inference . The Alismatis Rhizoma Alzheimer's study (quality 6) is explicitly described as preliminary with no significance reached for BDNF outcomes . The ACL clinical study (quality 7) reported a significant volume deficit (1726.5 vs 1857.6 mmΒ³, P<0.001) but had only four re-rupture events for the risk inference .
The portfolio's greatest scientific strength lies in translational immunology and multi-omics integration, evidenced by the BET-family (9/10) and microbiome (8/10) papers. The greatest weakness is inconsistent rigor: simulation-only validation in engineering works, single-donor limitations in immunotherapy preprints, and unsystematic review methodology. The extreme cross-disciplinary breadthβspanning fuzzy logic, semiconductor physics, clinical orthopedics, chromatin biology, and nanomedicineβmost plausibly reflects multiple individuals sharing the name rather than one scientist's work, though NRF-Korea funding connects several 2017β2026 biological studies. What would change this assessment: OpenAlex author-ID resolution, confirmed co-authorship networks, and citation metrics.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.